Lotus Eye Hospital and Institute Limited

Informe acción NSEI:LOTUSEYE

Capitalización de mercado: ₹1.7b

Lotus Eye Hospital and Institute Dirección

Dirección controles de criterios 4/4

El CEO de Lotus Eye Hospital and Institute's es Kuttapalayam Ramalingam, nombrado en Aug 2020, tiene una permanencia de 3.67 años. posee directamente un 1.43% de las acciones de la empresa, con un valor de ₹17.77M. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 4.3 años, respectivamente.

Información clave

Kuttapalayam Ramalingam

Chief Executive Officer (CEO)

₹1.2m

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO4.1yrs
Participación del CEO1.4%
Permanencia media de la dirección4yrs
Promedio de permanencia en la Junta Directiva4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Aug 21
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07
Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08
We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11
MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30
Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20
Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21
The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27
Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06
Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

CEO

Kuttapalayam Ramalingam (74 yo)

4.1yrs

Permanencia

₹1,200,000

Compensación

Dr. Kuttapalayam Songappan Ramalingam, M.D., serves as an Executive Director at Lotus Eye Hospital and Institute Limited since February 10, 2021. Dr. Ramalingam serves as Chief Executive Officer at Lotus E...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Kuttapalayam Ramalingam
CEO & Executive Director4.1yrs₹1.20m1.43%
₹ 23.7m
Ramanujam Reghunathan
Chief Financial Officer2.3yrs₹1.70msin datos
Mohanmenon Menon
Company Secretary & Compliance Officer2.6yrs₹1.08msin datos
Sangeetha Sundaramoorthy
MD & Director4yrs₹3.09m18.84%
₹ 311.5m
Rajkumar Sundaramoorthy
Vice President of Administration6.3yrssin datos0.21%
₹ 3.4m

4.0yrs

Permanencia media

67yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LOTUSEYE se considera experimentado (3.6 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Kuttapalayam Ramalingam
CEO & Executive Director3.6yrs₹1.20m1.43%
₹ 23.7m
Sangeetha Sundaramoorthy
MD & Director4.8yrs₹3.09m18.84%
₹ 311.5m
Rajkumar Sundaramoorthy
Vice President of Administration4.7yrssin datos0.21%
₹ 3.4m
Devarayapuram Kaarthikeyan
Non-Executive Independent Director16.9yrs₹200.00ksin datos
Kavetha Sundaramoorthy
Chairman of the Board8.3yrs₹150.00k18.78%
₹ 310.5m
Yogesh Shah
Non-Executive Independent Director16.9yrs₹200.00ksin datos
Marappa Alagiriswamy
Non-Executive Independent Director12.3yrs₹200.00ksin datos
Sengodagounder Natesan
Independent Director3.7yrs₹200.00ksin datos
Gopalakrishnan Veeramani
Independent Non-Executive Director1.8yrs₹200.00ksin datos
Perumalsamy Mahendran
Independent Non-Executive Director1.6yrs₹175.00ksin datos

4.8yrs

Permanencia media

75yo

Promedio de edad

Junta con experiencia: La junta directiva de LOTUSEYE se considera experimentada (4.3 años de antigüedad promedio).